Open label randomized trial of treatment by perospirone and aripiprazole for schizophrenia patients considering the drug susceptibility gene.

Trial Profile

Open label randomized trial of treatment by perospirone and aripiprazole for schizophrenia patients considering the drug susceptibility gene.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2015

At a glance

  • Drugs Aripiprazole (Primary) ; Perospirone (Primary)
  • Indications Schizophrenia
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 01 Sep 2015 Results presented at the 28th Annual Congress of the European College of Neuropsychopharmacology
    • 09 Oct 2013 Results presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
    • 01 Jan 2013 Results published in Progress in Neuro-Psychopharmacology and Biological Psychiatry.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top